[Therapeutic effect of levamisole plus HBV vaccine and dipyridamole on patients chronically infected by HBV with precore mutation].
OBJECTIVE
To evaluate the incidence of precore mutation in HBeAg negative HBV infected patients and the therapeutic effect of the immune therapy (levamisole + HBV vaccine + dipyridamole) on patients chronically infected by HBV with precore mutation.


METHODS
The precore region of HBV from the HBeAg (-) chronic hepatitis patients was sequenced and the patients suffered from HBV with precore mutation were treated with immune therapy.


RESULTS
The precore mutation rate was 10/12. The therapeutic effect of the immune therapy on the precore mutation patients (5/7) was better than that on the HBsAg(+), HBeAg(+) patients (2/11), P less than 0.05.


CONCLUSIONS
The precore mutation rate was quite high in the HBsAg(+), HBeAg(-) patients we studied. The immune-therapy has some therapeutic effects on the patients with precore mutation. But the number of cases was too small, further study is needed.
Luo
Xiao-lian
XL
The Third Peoples Hospital, Wuhu Anhui 241000, China.
Wang
Yan
Y
Tian
Geng-shan
GS
Fu
Xi-xian
XX
Wang
Yong-yi
YY
Wei
Lai
L
Chen
Jie
J
Su
Sheng
S
Fan
Gong-ren
GR
D000293:Adolescent; D000328:Adult; D002648:Child; D003131:Combined Modality Therapy; D004279:DNA, Viral / Q000097:blood; D004176:Dipyridamole / Q000627:therapeutic use*; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006515:Hepatitis B virus / Q000235:genetics / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000628:therapy* / Q000821:virology; D006801:Humans; D007167:Immunotherapy; D019259:Lamivudine / Q000627:therapeutic use; D007978:Levamisole / Q000627:therapeutic use*; D008875:Middle Aged; D009154:Mutation
D004279:DNA, Viral; D017325:Hepatitis B Vaccines; D007978:Levamisole; D019259:Lamivudine; D004176:Dipyridamole